# PANCREATITIS

## ACUTE PANCREATITIS

## Pathogenesis

• Pancreatic duct and acinar injury via direct or indirect toxicity → impaired secretion and premature activation of digestive enzymes → autodigestion and acute inflammation

## 原因 (_NEJM_ 2016;375:1972)

• **Gallstones** (40%): ♀ > ♂; usually due to small stones (<5 mm) or microlithiasis/sludge

• **Alcohol** (30%): ♂ > ♀; 4–5 drinks/day over ≥5 yrs; usually chronic with acute flares

• Metabolic: hypertrig. (2–5%; TG >1000; type I & V familial hyperlipemia); hyperCa

• Drugs (<5%): 5-ASA, 6-MP/AZA, ACEI, cytosine, didanosine, dapsone, estrogen, furosemide, isoniazid, MNZ, pentamidine, statins, sulfa, thiazides, tetracycline, valproate

• Anatomic: divisum, annular pancreas, duodenal duplication cysts, Sphincter of Oddi dysfxn

• Autoimmune (qv)

• Familial: suspect if early onset (age <20 y); cause acute and chronic pancreatitis (qv)

• Infections: ascaris, clonorchis, coxsackie, CMV, EBV, HIV, mumps, mycoplasma, TB, toxo

• Ischemia: shock, vasculitis, cholesterol emboli

• Neoplastic: panc/ampullary tumors, mets (RCC most common, breast, lung, melanoma)

• Post ERCP (5%): Ppx with PR indomethacin can ↓ sx; temporary panc duct stent if high risk

• Trauma: blunt abdominal trauma, post-pancreatic/biliary surgery

## 臨床表現

• **Epigastric abdominal or LUQ pain (90%)**, only ½ with bandlike pain radiating to back

• 10% pain-free (due to analgesic/steroid use, immunosuppressed, ΔMS, ICU, post-op), ∴ ✔ amylase/lipase in unexplained shock

• **N/V (90%),** abd tenderness/guarding, ↓ bowel sounds, jaundice if biliary obstruction

• Ddx: acute cholecystitis, perforated viscus, SBO, mesenteric ischemia, IMI, AAA leak, distal aortic dissection, ruptured ectopic pregnancy

• **Early phase** (<1 wk): possible SIRS ± organ failure; **late** (>1 wk): local complications (qv)

## Diagnostic studies (_Am J Gastro_ 2013;108:1400)

• **Dx requires 2 of 3:** characteristic abd pain; lipase or amylase >3× ULN; ⊕ imaging

• Laboratory: levels of amylase & lipase do _not_ correlate with severity of disease

↑ **amylase**: rises within hrs, normalizes within 3–5 d (faster than lipase)

false ⊖: 20% EtOH pancreatitis; 50% hypertriglyceridemia (assay interference)

false ⊕: other abd or salivary gland process, acidemia, ↓ GFR, macroamylasemia

↑ **lipase**: longer t½ than amylase

\>3× ULN 99% sensitive, 99% specific for acute pancreatitis

\>10k has 80% PPV for biliary dx, 99% NPV for EtOH (_Dig Dis Sci_ 2011;56:3376)

false ⊕: renal failure, other abd process, DKA, HIV, macrolipasemia

ALT >3× ULN has 95% PPV for gallstone pancreatitis (_Am J Gastro_ 1994;89:1863)

• Imaging studies (_Am J Gastro_ 2013;108:1400)

**Abd U/S:** typically not useful to visualize pancreas (obscured by bowel gas), but _should be ordered for all 病人 to 排除 biliary etiology_ (ie, gallstones, BD dilatation)

**Abd CT:** not rec for initial eval unless dx unclear (local complic. not yet visible & concern for AKI with IV contrast). However, if persistent pain and/or 臨床deterioration after 48–72 h, CT(I+) useful to 排除 local complications (necrosis, fluid collections).

MRI/MRCP: Can detect necrosis; also used to assess for stones & ductal disruption

Endoscopic U/S (EUS): useful for occult biliary disease (microlithiasis)

## Severity (_Gut_ 2013;62:102)

• Severity defined by presence of organ failure (AKI, resp failure, GIB, shock) & local or systemic complic. (panc necrosis, fluid collections, gastric outlet obstrxn, splenic & PVT).

**Mild:** 80% of cases; no organ failure or local/systemic complications; low mortality

**Moderate:** transient (<48 h) organ failure ± local/systemic complications, high morbidity

**Severe:** persistent (>48 h) organ failure, very high mortality

## Prognosis (_NEJM_ 2016;375:1972)

• **Ranson’s, APACHE II:** predict severity at 48 h using multiple physiolog. criteria; poor PPV

• **BISAP:** simple 5-point scoring system (BUN >25, impaired MS, SIRS, age >60 y, pleural effusion) used within first 24 h; score ≥3 predicts ↑ risk of organ failure, mortality

• **CTSI:** CT data at 48–72h (fluid collect., necrosis) to predict mortality; can lag behind clinical

## 治療 (_NEJM_ 2016;375:1972; _Am J Gastro_ 2017;112:797)

• **Fluid resuscitation:** _aggressive in 1__st_ _24 hrs, even if mild._ 20 ml/kg IVB → 3 ml/kg/hr. Goal to ↓ BUN & Hct over 12–24 h. ✔ UOP. LR may be superior to NS (↓ SIRS; avoid if ↑ Ca).

• **Nutrition** (_NEJM_ 2014;317:1983)

Early enteral feeding encouraged, though not superior to oral feeding at 72 h

Mild: Start feeding once withoutut N/V or ileus; may not need to be completely pain free. Low-fat low-residue diet as safe as liquid diet and a/w shorter LOS.

Severe: early (w/in 48–72 h) enteral nutrition indicated and preferred over TPN b/c ↓ infectious complications, organ failure, surgical interventions, and mortality.

• **Analgesia:** IV opioids (monitor respiratory status, adjust dosing if ↑ renal impairment)

• **Gallstone pancreatitis:** urgent (w/in 24 h) ERCP with sphincterotomy if cholangitis, sepsis, or Tbili ≥5. If mild, CCY during initial hosp to ↓ risk of recurrence (_Lancet_ 2015;386:1261); defer surgery if necrotizing panc. until improvement in inflam. & fluid collections.

• **Hypertriglyceridemia:** insulin gtt (activates lipoprotein lipase), fibrates, ± apheresis

• No role for ppx 抗生素 in absence of infectious complications (_World J Gastro_ 2012;18:279)

## Complications

• Systemic: ARDS, abdominal compartment syndrome, AKI, GIB (pseudoaneurysm), DIC

• Metabolic: hypocalcemia, hyperglycemia, hypertriglyceridemia

• Fluid collections:

**Acute fluid collection:** seen early, not encapsulated, most resolve within 1–2 wk without Rx

**Pseudocyst:** ~4 wk after initial attack, encapsulated. No need for Rx if asx (regardless of size/location). If sx → endoscopic (_Gastro_ 2013;145:583) vs. perc/surg drainage.

• Pancreatic necrosis: Nonviable pancreatic tissue. CT-guided FNA if infection suspected.

**Sterile necrosis:** if asx, can be managed expectantly, no role for ppx 抗生素

### Infected necrosis (5% of all cases, 30% of severe): high mortality. Rx with carbapenem or MNZ+FQ. If stable, defer drainage to >4 wk to allow liquefication and WOPN (qv). If sx or unstable, perc drainage & minimally invasive surg debridement or endoscopic necrosectomy superior to open necrosectomy (_NEJM_ 2010;362:1491).

### WOPN (walled off panc. nec.): fibrous wall surrounds necrosis over ≥4 wk; endoscopic or perc. drainage (preferred over open necrosectomy) if infected or symptomatic

# CHRONIC PANCREATITIS

## Pathogenesis & etiology (_Gastro_ 2013;144:1292; _BMJ_ 2018;361:k2126)

• Often recurrent acute attacks → inflam infiltrate → fibrosis → loss of exocrine & endocrine tissue. Pancreatic insufficiency (DM, fat/protein malabsorption) when 90% panc fxn lost.

• TIGAR-O: **T**oxins (60–80% due to EtOH; smoking), **I**diopathic, **G**enetic (PRSS1, SPINK1, CFTR, CTRC, CASR), **A**utoimmune, **R**ecurrent panc., **O**bstruction

## 臨床表現

• Epigastric pain, N/V; over time can be painless; signs of exocrine insuff (steatorrhea, wt loss) or endocrine insuff (DM: polydipsia, polyuria)

## Diagnostic studies (_Pancreas_ 2014;43:1143)

• Labs: amylase/lipase ↑ early, may be 正常 later. ⊕ fecal fat, ↓ stool elastase & A1AT. Mixed TG breath test alternative to stool elastase. ✔ A1c, consider IgG4/ANA & genetic testing if young or ⊕ FHx. If dx with CP, measure baseline fat-soluble vitamins (ADEK).

• Imaging: Ca2+ on KUB/CT. ERCP/MRCP/EUS: high sens for dx; may show stricture, dilated ducts. IV secretin stim with MRI may ↑ dx yield. Panc fxn test not widely available.

## 治療 (_Gastro_ 2011;141:536; _Lancet_ 2016;387:1957)

• Pancreatic enzyme replacement (may ↓ pain by reducing CCK). Rx routine vitamin D & Ca.

• Pain control: smoking & EtOH cessation, analgesics, pregabalin, endoscopy (stone removal or stenting strictures), celiac nerve plexus block, surgery

## Complications

• Pseudocysts, pseudoaneurysms, pancreatic ascites or pleural eff., 13× ↑ **risk of panc Ca**

# AUTOIMMUNE PANCREATITIS

## Pathogenesis (_Am J Gastro_ 2018;113:1301)

• Type 1: lymphoplasmacytic sclerosing panc. with dense fibrosis; ↑ IgG4; high relapse

• Type 2: idiopathic duct-centric pancreatitis; minimal IgG4; a/w IBD; fewer relapses

## 臨床表現

• **Abdominal pain**, can 表現為 obstructive jaundice and panc mass mimicking panc Ca

• Can be primary, or in a/w IgG4 cholangitis, salivary gland disease (eg, Sjögren’s), mediastinal or RP fibrosis, interstitial nephritis, autoimmune thyroiditis, UC/PSC, RA

## Diagnosis

• Labs: cholestatic LFTs (↑ Aφ > AST/ALT), ↑ γ-globulins and IgG4, ⊕ ANA, RF

• HISORt criteria: Histology, Imaging (“sausage pancreas”, bile duct stricture), Serology, other Organ involvement, Response to therapy

## 治療

• Corticosteroids 1st\-line; immunomod. (AZA, MMF, cyclophosphamide, rituximab) if relapse
